Dunkley S, Gibson J, Iland H, Li C, Joshua D
Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Leuk Lymphoma. 1999 Nov;35(5-6):623-6. doi: 10.1080/10428199909169629.
The association of leukemia and multiple myeloma is well described usually as a complication of chemotherapy but also in the absence of chemotherapy or at diagnosis. Such leukemias are typically acute myeloid leukemia (AML), particularly myelomonocytic subtype, and cases of acute promyelocytic leuke (APL) are rarely reported. Controversy exists as to whether myeloma and AML originate from a single haematopoietic progenitor or arise from different cell lineages. We report a case of a 58 year old female who developed APL 10 months following diagnosis of nonsecretory light chain (kappa) myeloma which had been treated with local spinal irradiation and low dose oral melphalan and prednisone. Clonality had originally been demonstrated by light chain restriction (kappa) of her bone marrow plasma cells whilst immunoglobulin heavy chain and T cell receptor genes were germ line. At development of APL cytogenetics revealed t(15;17) and PML-RAR fusion gene was detected by RT-PCR. The patient was treated with all-trans retinoic acid (ATRA) and received 2 cycles of consolidation chemotherapy with Idarubicin. Following this therapy the t(15;17) and PML-RAR were both undetectable whilst the clonal population of kappa staining plasma cells persisted. This particular patient represents a rare case of APL complicating multiple myeloma with persistence of the myeloma clone but disappearance of PML-RAR alpha RNA following therapy. This case study appears to support the argument that the APL and myeloma originated from distinct cell lineages.
白血病与多发性骨髓瘤的关联通常被描述为化疗的并发症,但在未进行化疗时或诊断时也会出现。此类白血病通常为急性髓系白血病(AML),尤其是粒单核细胞亚型,而急性早幼粒细胞白血病(APL)病例则鲜有报道。骨髓瘤和AML是源自单一造血祖细胞还是源自不同细胞谱系,目前仍存在争议。我们报告一例58岁女性病例,该患者在诊断为非分泌型轻链(kappa)骨髓瘤10个月后发生APL,此前该患者接受了局部脊髓照射以及低剂量口服美法仑和泼尼松治疗。最初通过其骨髓浆细胞的轻链限制(kappa)证明了克隆性,而免疫球蛋白重链和T细胞受体基因呈种系状态。发生APL时,细胞遗传学显示t(15;17),通过逆转录聚合酶链反应(RT-PCR)检测到PML-RAR融合基因。该患者接受了全反式维甲酸(ATRA)治疗,并接受了2个周期的伊达比星巩固化疗。经过此治疗后,t(15;17)和PML-RAR均检测不到,而kappa染色浆细胞的克隆群体持续存在。该特殊患者代表了APL并发多发性骨髓瘤的罕见病例,骨髓瘤克隆持续存在,但治疗后PML-RARαRNA消失。该病例研究似乎支持APL和骨髓瘤源自不同细胞谱系的观点。